These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31898869)

  • 41. A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease.
    Sinclair G; Choy FY; Humphries L
    Blood Cells Mol Dis; 1998 Dec; 24(4):420-7. PubMed ID: 9851895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ophthalmological findings in Gaucher disease.
    Eghbali A; Hassan S; Seehra G; FitzGibbon E; Sidransky E
    Mol Genet Metab; 2019 May; 127(1):23-27. PubMed ID: 31047801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histological characterisation of visceral changes in a patient with type 2 Gaucher disease treated with enzyme replacement therapy.
    Tezuka Y; Fukuda M; Watanabe S; Nakano T; Okamoto K; Kuzume K; Yano Y; Eguchi M; Ishimae M; Ishii E; Miyazaki T
    Blood Cells Mol Dis; 2018 Feb; 68():194-199. PubMed ID: 27866810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gaucher disease: in vivo evidence for allele dose leading to neuronopathic and nonneuronopathic phenotypes.
    Zhao H; Bailey LA; Elsas LJ; Grinzaid KA; Grabowski GA
    Am J Med Genet A; 2003 Jan; 116A(1):52-6. PubMed ID: 12476451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation.
    Ida H; Rennert OM; Iwasawa K; Kobayashi M; Eto Y
    Hum Genet; 1999; 105(1-2):120-6. PubMed ID: 10480365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes.
    Orenstein M; Barbouth D; Bodamer OA; Weinreb NJ
    Orphanet J Rare Dis; 2014 Mar; 9():45. PubMed ID: 24685312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intrafamilial clinical variability of type 1 Gaucher disease in a French-Canadian family.
    Choy FY
    J Med Genet; 1988 May; 25(5):322-5. PubMed ID: 3385740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pulmonary manifestations in young Gaucher disease patients: Phenotype-genotype correlation and radiological findings.
    Gawad Tantawy AA; Moneam Adly AA; Madkour SS; Salah El-Din NY
    Pediatr Pulmonol; 2020 Feb; 55(2):441-448. PubMed ID: 31774256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [From gene to disease; Gaucher disease].
    Hollak CE; Boot RG; Poorthuis BJ; Aerts JM
    Ned Tijdschr Geneeskd; 2005 Sep; 149(39):2163-6. PubMed ID: 16223076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three Gaucher-disease-producing mutations in a patient with Gaucher disease: mechanism and diagnostic implications.
    Beutler E; Liebman H; Gelbart T; Stefanski E
    Acta Haematol; 2000; 104(2-3):103-5. PubMed ID: 11154983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
    Dandana A; Ben Khelifa S; Chahed H; Miled A; Ferchichi S
    Pathobiology; 2016; 83(1):13-23. PubMed ID: 26588331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
    McEachern KA; Nietupski JB; Chuang WL; Armentano D; Johnson J; Hutto E; Grabowski GA; Cheng SH; Marshall J
    J Gene Med; 2006 Jun; 8(6):719-29. PubMed ID: 16528760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gaucher disease: a heterogeneous clinical complex for which effective enzyme replacement has come of age.
    Frenkel EP
    Am J Med Sci; 1993 May; 305(5):331-44. PubMed ID: 8097903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings.
    Ramadža DP; Zekušić M; Žigman T; Škaričić A; Bogdanić A; Mustać G; Bošnjak-Nađ K; Ozretić D; Ohno K; Fumić K; Barić I
    Eur J Paediatr Neurol; 2021 May; 32():66-72. PubMed ID: 33836415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gaucher disease: functional expression of the normal glucocerebrosidase and Gaucher T1366G and G1604A alleles in Baculovirus-transfected Spodoptera frugiperda cells.
    Choy FY; Wei C; Levin D
    Am J Med Genet; 1996 Oct; 65(3):184-9. PubMed ID: 9240741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease.
    Jiang W; Yi M; Maegawa GHB; Zhang H
    J Hum Genet; 2020 Mar; 65(3):345-349. PubMed ID: 31822786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gaucher disease with prenatal onset and perinatal death due to compound heterozygosity for the missense R131C and null Rec Nci I GBA mutations.
    Goebl A; Ferrier RA; Ferreira P; Pinto-Rojas A; Matshes E; Choy FY
    Pediatr Dev Pathol; 2011; 14(3):240-3. PubMed ID: 20946052
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of neurogenetics in Gaucher disease.
    Brady RO; Barton NW; Grabowski GA
    Arch Neurol; 1993 Nov; 50(11):1212-24. PubMed ID: 8215980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.